Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones [Yahoo! Finance]
Neumora Therapeutics, Inc. (NMRA)
Company Research
Source: Yahoo! Finance
KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026 Plans to conduct NMRA-215 clinical program in 2026 following class-leading preclinical data from diet induced obesity model Advancing NMRA-511 following Phase 1b results demonstrating clinically meaningful effect on CMAI total score Cash, cash equivalents and marketable securities expected to support operations into the third quarter of 2027 WATERTOWN, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced key pipeline updates and anticipated 2026 milestones that support the Company's mission to redefine neuroscience drug development with the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients living with
Show less
Read more
Impact Snapshot
Event Time:
NMRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NMRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NMRA alerts
High impacting Neumora Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NMRA
News
- Neumora Therapeutics (NASDAQ:NMRA) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
- Neumora Therapeutics (NASDAQ:NMRA) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $8.00 price target on the stock.MarketBeat
- Neumora Therapeutics (NASDAQ:NMRA) was given a new $6.00 price target on by analysts at Mizuho.MarketBeat
- Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease Agitation [Yahoo! Finance]Yahoo! Finance
- Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming MilestonesGlobeNewswire
NMRA
Earnings
- 11/6/25 - Miss
NMRA
Sec Filings
- 1/12/26 - Form 8-K
- 1/9/26 - Form 4
- 1/9/26 - Form 4
- NMRA's page on the SEC website